CD3D and neoplasm: Incorporating the cytoplasmic tails of CD3ε, CD3γ, and CD3δ into CAR constructs has been shown to improve anti-tumor responses, while lowering cytokine secretion and early exhaustion compared to second-generation ζCARs, challenging the current gold-standard of ζ-based CAR T-cell therapy.